P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity.

@article{JalotaBadhwar2015P7170AN,
  title={P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity.},
  author={Archana Jalota-Badhwar and Dimple R Bhatia and Srinivas Boreddy and Asavari A. Joshi and Magesh Venkatraman and Nikesh K Desai and Sarika Chaudhari and Julie S. Bose and Lakshmi Sireesha Kolla and Vijaykumar B Deore and Nilambari Yewalkar and Sanjay Kumar and Rajiv B Sharma and Anagha A. Damre and Avinash More and Somesh Sharma and Veena R. Agarwal},
  journal={Molecular cancer therapeutics},
  year={2015},
  volume={14 5},
  pages={1095-106}
}
The mTOR pathway is often upregulated in cancer and thus intensively pursued as a target to design novel anticancer therapies. Approved and emerging drugs targeting the mTOR pathway have positively affected the clinical landscape. Recently, activin receptor-like kinase 1 (ALK1), belonging to the TGFβ receptor family, has been reported as an emerging target for antiangiogenic cancer therapy. Here, we describe a novel orally efficacious compound, P7170, that inhibits mTORC1/mTORC2/ALK1 activity… CONTINUE READING
3 Citations
43 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Similar Papers

Loading similar papers…